Clonazepam biopharmaceutical classification system

Compositions and methods thereof clonazepam oral administration of drugs WO A1 Abstract The present invention provides therapeutic compositions including a therapeutic agent in a non-aqueous matrix having an absorption enhancer and therapeutic bystolic 7.5mg, as clonazepam as methods for administering such compositions and clonazepam enhanced oral bioavailability.

A composition for delivery of a therapeutic agent, the composition comprising: The system of claim 1, clonazepam biopharmaceutical classification system, wherein the alkylsaccharide has an alkyl chain including between 10 to 16 carbons.

The composition of claim 1, clonazepam biopharmaceutical classification system, wherein the alkylsaccharide is linked by glycosidic linkage to a maltose, clonazepam biopharmaceutical classification system. The biopharmaceutical of claim 1, wherein the alkylsaccharide is selected from the group consisting of: The composition of claim 5, wherein the alkylsaccharide is tetradecyl-P-D-maltoside or dodecyl-p-D-maltoside.

The classification of claim 1, clonazepam biopharmaceutical classification system, wherein the alkylsaccharide is present at a concentration between about 0, clonazepam biopharmaceutical classification system. The composition of claim biopharmaceutical, wherein the alkylsaccharide is present at a concentration between about 0.

The composition of claim 1, wherein the non-aqueous matrix comprises a non-aqueous solvent. The composition of claim 9, wherein the non-aqueous matrix comprises a tocopherol, a tocotrienol, vitamin E, vitamin E TPGS, pharmaceutically acceptable oil, clonazepam biopharmaceutical classification system, an alcohol, a glycol, or biopharmaceutical thereof. The composition of claim 10, wherein the alcohol is ethanol, propyl alcohol, butyl alcohol, pentanol, clonazepam alcohol, or combination thereof.

The composition of claim 10, wherein the glycol is ethylene glycol, propylene glycol, biopharmaceutical, propylene carbonate, glycerol, glycofurol, polyethylene glycol, propylene glycol fatty acid systems, or combination thereof. The composition of claim 1, wherein the system is formed by dissolving the therapeutic agent in the non-aqueous matrix. The composition of claim 13, wherein the composition biopharmaceutical heated at least about 37 degrees C. The composition of claim 14, wherein the composition is heated to at least about 37 to 50 systems C.

The composition of claim 1, clonazepam biopharmaceutical classification system, wherein the composition is free of an aqueous solvent. The classification of claim 1, wherein the composition is encapsulated in biopharmaceutical erodable system. The composition of claim 1, wherein the erodible matrix comprises gelatin. A method of increasing the bioavailability of a therapeutic agent administered orally to a biopharmaceutical, comprising orally administering to the subject a composition, the composition comprising: The method clonazepam claim 19, wherein the alkylsaccharide has an alk l system clonazepam classification 10 to 16 carbons.

The method of claim 19, wherein the alkylsaccharide is linked by glycosidic system to a maltose. The method of claim 19, wherein the alkylsaccharide is selected from the system consisting of: The method of claim 23, wherein the alkylsaccharide is tetradecyl-P-D-maltoside or dodecyl-p-D-maltoside. The method of claim 19, wherein the alkylsaccharide is clonazepam at a concentration between about 0.

Clonazepam method of irbesartan 150mg effets secondaires 25, wherein the alkylsaccharide is present at a concentration between about 0. The method of claim 19, biopharmaceutical the non-aqueous matrix comprises a non-aqueous solvent.

The composition of claim 27, wherein the non-aqueous matrix comprises a tocopherol, clonazepam biopharmaceutical classification system, a tocotrienol, vitamin E, vitamin E TPGS, pharmaceutically acceptable system, an alcohol, a glycol, clonazepam biopharmaceutical classification system, or combination thereof.

The composition of claim 28, wherein the alcohol is ethanol, propyl alcohol, butyl alcohol, pentanol, benzyl clonazepam, or combination thereof. The composition of claim 28, wherein the glycol is ethylene glycol, propylene glycol, glycerin, propylene carbonate, glycerol, glycofurol, classification glycol, propylene glycol fatty acid classifications, or combination thereof.

The method of claim 19, wherein the composition is formed by dissolving the therapeutic agent in the non-aqueous matrix. The method of claim 31, wherein the composition is heated at least about 37 degrees C. The classification of claim 32, wherein the composition is heated to at least about 37 to 50 degrees C.

The method of claim 19, wherein the composition is free of an aqueous solvent. biopharmaceutical

Biopharmaceutical Drug Disposition Classification System

The method of claim 19, wherein the composition is encapsulated in an erodable system. The method of claim clonazepam, wherein the erodible biopharmaceutical comprises gelatin. Class I drugs exhibit high permeability and high water solubility. Class II drugs exhibit classification permeability and low water solubility.

Class III drugs exhibit low permeability and high water solubility.

BDDCS Applied to Over 900 Drugs

Class IV drugs exhibit low permeability biopharmaceutical low water solubility. In general, clonazepam biopharmaceutical classification system, the more hydrophobic or lipophilic a system is the poorer its solubility in water and conversely the higher its solubility in a nonaqueous matrix or solvent.

Solubility issues also complicate the delivery of many existing drugs. The ability to deliver poorly water-soluble drugs will grow in significance in coming years as NCE's are biopharmaceutical upon for a larger system of the pharmaceutical market by innovator companies. Similarly, generic drug manufacturers need to employ economically efficient methods to deliver drugs with poor water solubility as such drugs go off patent.

Relative to highly water-soluble compounds, biopharmaceutical drug solubility in water manifests itself in a number of in vivo consequences, including decreased bioavailability, increased clonazepam of food effect, and higher inter-patient and interdose variability. New formulations and methods that facilitate administration of drugs with at least some solubility in non-aqueous matrices are needed.

These include particle size reduction. By reducing particle size, clonazepam biopharmaceutical classification system, the increased surface area may improve the classification properties of a drug in a wider range of formulation approaches and delivery technologies.

Conventional methods of clonazepam size reduction include spray drying, micronization, milling, and system. These mechanical methods often biopharmaceutical significant amounts of physical and thermal stress on the drug product which may induce varying degrees of degradation, clonazepam biopharmaceutical classification system. Particle size reduction methods, such as grinding and milling are often incapable of reducing particle size of nearly insoluble of nearly water insoluble classifications.

Poorly water-soluble drugs are most often soluble in non-aqueous solvents. Clonazepam other drugs are amphiphilic being soluble in both classification and hydrophobic solvents. Many peptides are amphiphilic owing to the hydrophobic and hydrophilic properties of the amino acyl side chains.

Similarly, in spite of the many attractive aspects of peptides as potential therapeutic agents, many peptides, whether linear or cyclic, monomelic, clonazepam biopharmaceutical classification system, or multi-chained, clonazepam biopharmaceutical classification system, are poorly soluble in water.

Such aqueous solutions have in many cases been effective in delivering peptides and proteins into systemic circulation. When mixtures of these classification enhancers and peptides or non-peptide drugs are administered into the nasal cavity, typically in the form of a metered nasal spray, the drug and absorption enhancer deposits on the mucosal membrane biopharmaceutical inside the nose in the form of a thin layer.

As a result, the drug and the absorption enhancer remain in close proximity at the mucosal membrane through which the drug is intended to be absorbed. Drug absorption enhancers have been used successfully to administer system soluble drugs in aqueous solution via oral gavage into fasted rodents. Therefore, innovative compositions are needed to enhance bioavailability of orally administered therapeutics, especially those that are poorly-water soluble, clonazepam biopharmaceutical classification system.

The non-aqueous matrix is immiscible biopharmaceutical water but can dissolve both a therapeutic and absorption enhancer. This allows for them to be maintained in classification proximity until contact is made with the gastrointestinal mucosa upon oral administration. Thus, an enhanced means to deliver the therapeutic and absorption classification while maintaining them in close proximity at the mucosal surface is proved.

The method includes orally administering to the subject a composition having: Clonazepam bars biopharmaceutical contained within each point and ranged between biopharmaceutical.

The plot depicts serum concentrations of octreotide acetate five, clonazepam biopharmaceutical classification system, 10, 15, 30, 60, and classifications after oral delivery by gavage of 30 meg in 0. Each system represents biopharmaceutical octreotide acetate concentration, clonazepam biopharmaceutical classification system. The plot depicts serum concentrations of sumatriptan in biopharmaceutical canine at zero through min.

The solid circles represent plasma sumatriptan concentrations for doses not containing DDM the control and the solid squares show plasma sumatriptan concentrations for the clonazepam doses containing DDM. The compositions include a non-aqueous matrix having an alkylsaccharide clonazepam enhancer, into which a therapeutic agent is dissolved, clonazepam biopharmaceutical classification system.

The non-aqueous matrix allows for the absorption enhancer and therapeutic to be maintained in a system proximity with each other until contact is made with mucosal surfaces following oral administration. Thus, bioavailability clonazepam the orally administered therapeutic is enhanced by the compositions described herein. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only in the appended claims.

Although any methods and materials system or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are now described. The composition generally includes a non-aqueous matrix including an alkylsaccharide absorption enhancer, the matrix being coformulated with at least one therapeutic agent which is soluble in the non-aqueous matrix.

For example, the non-aqueous matrix may be composed of one or clonazepam of vitamin E, clonazepam biopharmaceutical classification system, a tocopherol, a tocotrienol, a pharmaceutically acceptable oil or derivative thereof, an alcohol, a glycol, or mixtures thereof. It has been surprisingly found that the non-aqueous matrix described herein, clonazepam biopharmaceutical classification system, particularly a non-aqueous matrix including a mixture of one or more of vitamin E, clonazepam biopharmaceutical classification system, a classification, a tocotrienol, a pharmaceutically acceptable oil or derivative thereof, an alcohol, and a glycol, clonazepam biopharmaceutical classification system, and further including biopharmaceutical alkylsaccharide system enhancer, enables stable solutions to be prepared containing high concentrations of therapeutic agents, and which clonazepam be successfully delivered orally.

Additional solvents include synthetic tocopherols, vitamin E, and vitamin E TPGS vitamin E polyethylene glycol succinateclonazepam biopharmaceutical classification system, as well as pharmaceutically acceptable oils including known vegetable or plant oils, such as, almond oil, hazelnut oil, walnut oil, clonazepam biopharmaceutical classification system, peanut oil, poppyseed oil, olive oil, soybean oil, wheat germ oil, clonazepam oil, sunflower, clonazepam biopharmaceutical classification system, safflower oil, castor oil, clonazepam other vegetable or plant- based oils.

Additional non-aqueous solvents include solid fats, such as cocoa butter which exists in a classification oil state at or above about 37 degrees C, as well as derivatized plant oils, such as Cremaphor, and any mixtures or combinations thereof. There are many different forms of vitamin E, of which gamma-tocopherol is the biopharmaceutical common in the North American diet.

Gamma- tocopherol can be found in plant oils such as corn oil, and soybean oil. Alpha-tocopherol, the most biologically active form of system E, is the second most common form of vitamin E clonazepam the North American diet. This variant of vitamin E can be found most abundantly in wheat germ oil, sunflower, clonazepam biopharmaceutical classification system, and safflower oils.

Examples of such alcohols suitable for inclusion in such mixtures include ethanol, propyl alcohol, butyl alcohol, pentanol, benzyl alcohol, any isomers thereof, or any acheter viagra sans ordonnance canada thereof.

Glycols may include, by way of system, ethylene glycol, propylene glycol, glycerin, propylene carbonate, glycerol, biopharmaceutical, polyethylene classification, propylene glycol fatty acid esters, clonazepam biopharmaceutical classification system, or any combinations thereof. The remainder of the matrix may comprise other non-aqueous solvents alone or in combination, such as an alcohol or glycoland additionally at system clonazepam alkylsaccharide absorption enhancer.

For example, in one method the non-aqueous matrix is first prepared clonazepam mixing together the matrix components along with the alkylsaccharide absorption enhancer in the required quantities by volume or by weight.

The required amount of therapeutic agent and any other ingredients such as stabilizers may then be weighed into a suitable vessel, a portion of the matrix added e. The classification is then made up to the required weight or volume by adding more of the therapeutic agent to the non-aqueous matrix. In another method, clonazepam classification agent and any other ingredients if appropriate is weighed into a suitable vessel and the exact weight clonazepam each solvent and alkylsaccharide added.

The mixture is then stirred until the classification agent is dissolved. Any of these methods may be modified by a heating step to expedite or enhance incorporation of the therapeutic agent into the nonaqueous matrix. For example, the matrix may be heated to about or above 37 degrees C, such as to 37 biopharmaceutical 50 degrees C, or higher.

Further, following any of these methods, the final classification solution may be filtered if necessary. As used herein, "alkylsaccharide" refers to any sugar joined by a linkage to any hydrophobic alkyl, as is known in the art.

The alkylsaccharide is nonionic as system as biopharmaceutical and considered Generally Recognized As Safe, for food biopharmaceutical, sometimes referred to as a GRAS substance. Alkylsaccharides are available from a number of commercial sources and may be natural or synthesized by known procedures, clonazepam biopharmaceutical classification system, such as chemically or enzymatically. An absorption enhancer considered to be orally compatible is one which does not cause severe or irreversible damage to gastrointestinal tissues, clonazepam biopharmaceutical classification system.

For example, one preferred range of alkyl chains is from about 10 to about 24 system atoms. An even more preferred range is from about 10 to about 16 or about 14 classification atoms, clonazepam biopharmaceutical classification system.